Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

$0.4 million increase in these unallocated research and development costs is spread out across personnel costs (increased headcount initiated last year, particularly with respect to non-clinical work in the celgosivir program), patent costs (advancement of MX-3253 patent applications) and other costs (higher level of activity in both the MX-3253 and MX-2401 programs).

We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis. We are currently focusing our resources on advancing the development of our non-partnered programs: celgosivir and MX-2401.

General and Corporate Expenses

General and corporate expenses in Q1/08 were $1.0 million (Q1/07: $0.8 million). Personnel costs were $0.5 million in Q1/08 (Q1/07: $0.5 million). The approximate $0.2 million increase in general and corporate costs in Q1/08 compared with Q1/07 is principally due to: (i) contract personnel in the Finance department engaged for internal controls, implementation of new accounting software and year end work; and (ii) greater legal and accounting costs.

Amortization

Amortization expense for equipment was approximately $0.1 million for Q1/08 (Q1/07: $0.1 million).

Amortization expense for intangible assets was approximately $0.1 million for Q1/08 (Q1/07: $0.2 million).

Other Income and Expenses

Interest income was $0.1 million for Q1/08 (Q1/07: $0.1 million).

Accretion expense related to the convertible royalty participation units for Q1/08 was $0.4 million (Q1/07: $0.3 million). This accretion expense is a non-cash expense resulting from accreting the liability component of the convertible royalty participation units to the maximum royalties payable of $29.5 million (will be reduced for actual royalties paid, any units converted into common shares and should the estimate of royalties payable decline below $29.5 million) over the estimated royalty payment te
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an agreement with inVentiv Health for the operational ... lead compound (BHV-0223). Biohaven is ... stage neuroscience compounds targeting the glutamatergic system. Clinical ...
(Date:4/1/2015)... , Mar. 30, 2015 Research and Markets ... addition of the "Blood Screening Market by ... Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product ... - Forecasts to 2019 " report to ... is expected to reach $2.55 billion by 2019 ...
(Date:4/1/2015)... 2015  Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology, presented data on the ... 2015 Experimental Biology conference in Boston, ... an ideal extension of Organovo,s capabilities to 3D ... in pharmaceutical research," said Keith Murphy , ...
(Date:4/1/2015)... ROCKVILLE, Md. , April 1, 2015 /PRNewswire/ ... developer of pathogen-specific therapies for serious infections and ... today announced that clinical data supporting the development ... degrade certain beta-lactam intravenous (IV) antibiotics within the ... of the gut microbiome for the prevention of ...
Breaking Biology Technology:Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
... operating income of $856,000, IRVINE, Calif., March ... developer of surgical products,and accessories used in angina-relieving ... and fiscal year ended December 31,2007., Sales ... a 24% decrease,from the prior year fourth quarter ...
... FRANCISCO, March 25 Medivation, Inc.,(Nasdaq: MDVN ... Bronson, Ph.D.,to vice president, regulatory and quality, Mohammad ... Mordenti, Ph.D., to vice,president, translational medicine., "As ... product candidate, we are,strengthening the team to lead ...
... MARINO, Calif., March 25 Epeius Biotechnologies,Corporation ... No. 7,347,998 for,Targeted Gene Delivery in vivo. ... the platform of highly advanced,biotechnologies embodied in ... by simple intravenous infusion, the Epeius,tumor-targeted gene ...
Cached Biology Technology:Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 7Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... recently discovered form of the protein that triggers blood ... of metastatic pancreatic cancer and primary breast cancer, according ... published online ahead of print in the International ... Proceedings of the National Academy of Sciences ). ...
... and hope to be a father, here,s another reason ... your waistline or metabolic disorders. That,s because scientists have ... did not show any signs of diabetes, passed this ... Sons don,t entirely dodge this genetic bullet eitherboth sons ...
... and the National Institutes of Health have obtained ground-breaking new ... play a role in the development of cancer cells. The ... and have just been published in Journal of Biological ... of proteases to force their way into the body., In ...
Cached Biology News:Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests 2Obese dads pass on predisposition to obesity and metabolic disorders to their kids 2Molecular discovery puts cancer treatment in a new perspective 2Molecular discovery puts cancer treatment in a new perspective 3
... ProteomeLab PA 800 is an automated, ... of Beckman Coulters ProteomeLab family of ... comprehensive range of automated protein characterization ... mapping, isoelectric focusing, carbohydrate profiling and ...
... Rapid-Screen cDNA Library Panels were designed for ... sets of PCRs to identify the desired ... performed in a 96-well "Master Plate," where ... clones. Having identified the positive well(s) by ...
... proteomic scale kinase profiling, quantitative measurement of ... built on the flexible and powerful Paraflo ... available as part of our comprehensive Protein ... Probe Content Our standard content ...
... System (Ruggedized Advanced Pathogen Identification Device) ... designed for field hospitals, mobile laboratories ... to its ruggedness, it is designed ... as the LightCycler instrument. By taking ...
Biology Products: